Johnson will be paying $2.5 billion in the ASR and Pinnacle . hip implant settlements
NEW YORK (Reuters) – A unit of Johnson & Johnson has agreed to pay an estimated $2.5 billion to settle thousands of lawsuits from individuals allegedly injured by the company's artificial hip implants, the company announced Tuesday.
The settlement, announced during a hearing in federal court in Ohio on Tuesday, would compensate an estimated 8,000 patients who underwent surgery to replace their hip implants, according to a statement from Johnson & Johnson unit Depuy Orthopaedics Inc and DePuy Hip Replacement lawyers for the victims.
al The company was defending more than 12,000 lawsuits in U.S. state and federal court over injuries allegedly caused by its metal-on-metal ASR hip-replacement systems, according to a regulatory filing.
Depuy recalled the ASR hip system in 2010, after data suggested that it failed at a higher-than-expected rate. At the time, the company had sold about 93,000 systems worldwide.
Metal hip implant systems like Depuy's ASR hips were designed to be more durable, replacing a traditional metal-on-plastic ball-and-socket design. Instead, some patients who received the ASR hips reported experiencing pain, swelling, joint dislocation and sometimes damage to the central nervous system, thyroid and heart.
The settlement would compensate plaintiffs who have undergone surgery to replace their hips as of August 31, 2013, the company said Tuesday. The company estimated that 8,000 plaintiffs would be eligible.
There is no cap on the amount of individual claims, according to Peter Flowers, one of the lead lawyers for the plaintiffs. Eligible U.S. plaintiffs can seek compensation for costs associated with their revision surgery, as well as payments of qualified liens by healthcare providers associated with the surgery, Flowers said.
You Can Opt To Continue The Lawsuit and Not Accept The Offer
Plaintiffs who opt not to participate in the program, or those who have not undergone revision surgery to replace their implants, will continue to litigate.
The company said it will continue to defend itself in the remaining lawsuits not resolved by the agreement. It also said that it expected the cost of the settlement program to be covered by reserves it had previously set aside, and did not expect to record an additional charge in connection with the agreement.
"The U.S. settlement program provides compensation for eligible patients without the delay and uncertainty of protracted litigation," said Andrew Ekdahl, president of Depuy Synthes Joint Reconstruction, in a statement.
The settlement is not subject to court approval, according to a Johnson & Johnson spokeswoman, Lorie Gawreluk.
Johnson and Johnson Faces Risperdal Lawsuits
The announcement comes just weeks after Johnson & Johnson announced it would pay $2.2 billion to resolve civil and criminal probes into its marketing of several medications, including the anti-psychotic drug Risperdal.
Johnson and Johnson Faces Vaginal Mesh Implant Lawsuit
The Ethicon subsidiary is also a defendant in more than 23,000 lawsuits over vaginal mesh implants, according to a quarterly filing with the U.S. Securities and Exchange Commission.
If you or a loved on has a failed DePuy Pinnacle or ASR and has needed revision surgery call us for a hip replacement lawyer. We are alo accepting Risperdal and vaginal mesh lawsuits.
We continue to accept nationwide vaginal mesh and bladder sling cases, Actos lawsuits, NuvaRing lawsuits, Dialysis medication lawsuits, Pradaxa lawsuits, Hip Replacement lawsuits, SSRI birth defect lawsuits, Tylenol lawsuits, Yaz lawsuits and others.
Nationwide vaginal mesh and bladder sling cases
Patients have been diagnosed with bladder cancer after consuming the diabetes drug Actos.
Chemical Toxins Leach V Dupont Class Action Lawyers
Patients diagnosed with kidney cancer, testicular cancer, ulcerative colitis and/or thyroid disease who are members of the Leach v. Dupont class. Leach class definition: a person who drank contaminated water for at least one year prior to December 3, 2004 from one of six named water districts, or specified private drinking water wells contaminated with C-8. The affected water districts are:
Patients diagnosed with kidney cancer, testicular cancer, ulcerative colitis and/or thyroid disease who are members of the Leach v. Dupont class. Leach class definition: a person who drank contaminated water for at least one year prior to December 3, 2004 from one of six named water districts, or specified private drinking water wells contaminated with C-8. The affected water districts are (1) Little Hocking, Ohion (2) Lubeck Public Service District, West Virginia (3) City of Belpre, Ohio (4) Tuppers Plains, Ohio (5) Mason County Public Service District, West Virginia (6) Village of Pomeroy, Ohio.
Chemical exposure lawyer Little Hocking,
Chemical exposure lawyer Lubeck Public Service District,
Chemical exposure lawyer Belpre,
Chemical exposure lawyer Tuppers Plains,
Chemical exposure lawyer Mason County Public Service District,
Chemical exposure lawyer West Virginia ,
Chemical exposure lawyer Village of Pomeroy
It does not matter where class member now reside, so long as they lived in one of the contaminated areas and drank the water at least one year effective December 3, 2004.
DePuy Hip Pinnacle and ASR Hip Implant Recall Lawyers
Faulty Metal-on-Metal Hip Implants.
We are actively pursuing new Fosamax femur fracture cases. Our intake criteria for these cases is as follows: (1) proof of at least 4 years of Fosamax use or other oral bisphosphonates; (2) fracture of the subtrochanteric or shaft area of the femur; (3) no or minimal trauma associated with the fracture; (4) 80 years old or younger at time of fracture.
Granuflo, Naturalyte Dialysis Mediction Lawyers
We are litigating cases aagainst Fresenius, the German manufacturer and distributor of GranuFlo and NaturaLyte dialysate products. These products are supposed to safely filter and cleanse the bloodGranuFlo/NaturaLyte has been directly linked to unsafe levels of bicarbonate in dialysis patients.
Accepting cases preferably for injuries arising after 2011. Organon/Merck’s vaginal ring contraceptive drug/device are being actively litigated in both state and federal venues, and have been since late 2007. Plaintiffs allege that NuvaRing increases a woman’s risk of blood clots, heart attack, and stroke above and beyond the risk that is mentioned in the label.
Pradaxa Excessive Bleeding Lawyers
Pradaxa is an anticoagulant drug indicated for patients who have been diagnosed with atrial fibrillation. Pradaxa was heralded as a treatment advance because it is easier to take than its competitor, it also can cause uncontrollable bleeding which cannot be stopped by any antidote. Accordingly, there have been bleeding events which have lasted for days. Some clients have been told that there is simply nothing medical science can do to stop the bleeding. People have died
Lexapro/Celexa, Zoloft, Prozac, Effexor, Wellbutrin and Pax Lawyers
SSRI antidepressant manufacturers, including Glaxo-SmithKline, Eli Lilly, Pfizer, and Forest Laboratories, alleging a variety of birth defects from prenatal exposure to these drugs. The products involved include Lexapro/Celexa, Zoloft, Prozac, Effexor, Wellbutrin and Paxil.
Stryker Hip Replacement Lawyers
Litigation against Stryker. “Rejuvenate” and “ABGII” stem implants were recalled in the summer of 2012, and the failure of these femoral stems has caused enormous damage for those patients as a result of “fretting” in the modular neck- stem junction, leading to corrosion and exposure to large amounts of metallic debris.
Tylenol Lawyers For Liver Damage
Branded Tylenol acetaminophen toxicity causing acute liver failure requiring hospitalization.
*Only for injuries that occurred before 4/10/2012 as well as from states with 3+ year SOLs and Discovery rules. Cardiovascular injuries caused by Drospirenone (DRSP), the active progestin component in these oral contraceptive pills. Deep Vein Thrombosis, Pulmonary Embolism, Blood Clots and certain types of Stroke.
Class Action Lawyer Network Depuy Pinnacle and ASR Hip Replacement lawyers are filing lawsuits for victims of the DePuy ASR and DePuy Pinnacle hip replacements.
About the DePuy Pinnacle
Like the ASR XL, the Depuy Pinnacle is a metal on metal system that was designed to last at least 10-15 years, but now, orthopedic surgeons are reporting that these devices have been failing within one to two years of being implanted into their patients. Doctors in England are now reporting that 49 percent of DePuy ASR XL hip implants have failed after six years.
DePuy Hip Replacement lawyers are filing lawsuits for victims of the failed Depuy Pinnacle and DePuy ASR Hip Replacements.
Although the ASR and Pinnacle are both metal on metal systems, there are significant differences between the two :
The ASR is a monoblock design whereas the Pinnacle uses a modular system.
The ASR cup is made of one solid piece of metal, whereas the Pinnacle has an outer shell.
The Pinnacle is designed in such a way that the surgeon has the option to place a metal, ceramic or polyethylene liner inside the metal outer cup.
Both of these have had problems and lawsuits have been filed.
Stryker has recalled a number of hip replacements including: Stryker Rejuvinate, Stryker ABG II and the Trident. Lawsuits are being filed against Stryker for implant failure of all these devices
Stryker recalled its Trident artificial hip in 2007 due to device failures in recipients. Previous plaintiffs have cited symptoms consistent with other defective metal-on-metal hip implants, along with one defect that was unique to the Trident device: Many recipients claimed of hearing a loud squeaking noise coming from their hip region after receiving this particular model.
Stryker recalls on the Rejuvinate and ABG II will effect thousands and the lawsuits are coming in in mass. The FDA has taken another look and is proposing changes to regulations that allowed two Stryker Corp. recalled hip implant systems to be deemed safe. But the move does little for the tens of thousands of patients already implanted with the faulty medical devices. The DePuy Pinnacle and ASR are other failed recalled hip replacements that have injured thousands of victims. The FDA proposed changes for the 510(k) Premarket Notification Process for the approval of metal-on-metal hip implants like those manufactured by Stryker and DePuy come very late for seniors burdened with painful revision surgeries.
In July 2012, after injured patients filed more than 60 adverse event reports with the FDA, Stryker issued a voluntary recall of its ABG II and Rejuvenate hip implant systems. Post-market surveillance revealed that a metal-on-metal junction in these devices can shed metal debris, causing pain and tissue damage that may require a revision surgery. Can the FDA actually step up to the plate and protect our citizens?
The FDA’s most recent proposal aims to standardize the requirements for how the agency accepts data, regardless of the submission or application type. The new regulation will require 510(k) submissions to be scrutinized by an institutional review board (IRB), a must for PMA applications.
The proposal for better practices in approval of medical devices like hip implants would become effective 180 days after publication, and the proposal to shift from 510(k) to PMA for metal hips would become effective 90 days after publication. Lawyers for Stryker and Depuy hip replacements are filing lawsuits for failed devices.
Hip Implnat lawyers in Miami, Fort Lauderdale, West Palm Beach, Ft Myers, Melbourne, Jacksonville, Pensacola, Tampa, Sarasota, Bradnenton, Ocala, Vero Beach and all of Florida are investigating claims by floridians against Stryker and DePuy for complications and revisions.
The DePuy Asr and DePuy Pinncale have been recalled, as wel as the Stryker ABG II Modular Stems and Rejuvuante for complications. The DePuy is a matal on metal while the Stryker's are metal component but, they both are having the same complications.
- Metal toxicity and ions in the blood
- High levels of Chromium or Cobalt in the blood
- pain and discomfort
- Dislocation at the site location
It should also be noted that hip implants in women have a 29 percent higher failure rate than in men, Medpage Today reported. Researchers at the Permanente Research Group in San Diego published the study in the February 2013 issue of JAMA Internal Medicine.
For a metal on metal hip implant lawyer call today
Class Action lawyers are seeking all recipients of the DePuy Pinnacle hip replacement to file their hip replacement lawsuits now. DePuy has reached a potentils fund agreement and time is limited. If you have a DePuy Pinncle we want to hear from you now. DePuy Hip Lawsuits May Result in Large Settlement Fund
Perry Larkin | February 13th, 2013 | Posted in Depuy Hip Recall
Compensation for DePuy HipManufacturer Johnson & Johnson (J&J), the parent company to the hip replacement manufacturer DePuy, is currently negotiating settlements for plaintiffs who have retained a DePuy hip lawyer to seek compensation due to complications from the implants. Sources say that the settlements could cost as much as $2 billion.
Insiders close to the defendants state that J&J cannot afford to allow the cases to go to trial and run the risk of having to pay massive jury awards in every one of these cases. In January of 2012, J&J indicted that $800 million had been reserved to settle lawsuits filed because of problems with DePuy hip implants. However, a spokeswoman for the company, Lorie Gawreluk, stated that evidence to be presented at trial will show that DePuy “acted appropriately and responsibly.”
Over 10,000 lawsuits pending due to DePuy hip problems
The exact reported number of lawsuits, according to a filing in November of 2012, is 10,100 lawsuits pending against DePuy and J&J. Approximately 7,240 of these cases have already been consolidated in multidistrict litigation (MDL) in Ohio federal court. Another 2,000 have been centralized in California state court. The remaining claims against DePuy await trial in local courts nationwide.
The plaintiffs’ executive committee is presided over by U.S. District Judge David A. Katz in Toledo. The co-lead council for the committee—Steven J. Skikos—has stated that the current focus of the plaintiffs is to prepare for trial. So far, the attorneys for the plaintiffs and the defense have reviewed over 50 million pages of documents linked to this litigation. At least 50 witness have been deposed.
Johnson & Johnson considering settlement of $2 billion
Three cases have been scheduled to go to trial with the first beginning on January 23 in Los Angeles. If J&J loses these early cases, a precedent may be set that would yield financial payouts that the company can’t afford. This is why the company is contemplating settling the cases for $2 billion. It’s a large settlement, but not unusual in cases such as this.
One example of a company that had to pay a vast amount similar to the suggested settlement amount from J&J is Merck & Co. who, in 2007, paid settlements for their painkiller Vioxx from a fund of $4.85 billion. Vioxx had been shown to double a patient’s risk of heart attack and stroke.
DePuy settlements would be calculated based on each plaintiff’s claim and the merits of the complaint.
Multiple problems linked to DePuy ASR hip implant
DePuy ASR hip replacements are reportedly prone to a number of severe problems including joint dislocations, bone fractures and infections. These devices have been connected to premature loosening, which has made hip revision surgery necessary. Also, shards of metal can break off from the implant and enter the patient’s bloodstream, causing tissue damage and joint death.
Over 10,000 lawsuits against DePuy are currently pending. $200,000 per plaintiff has been suggested as the amount each plaintiff should receive. Plaintiffs’ attorneys are alleged to have said that this figure is too low. A DePuy hip recall had been implemented in 2010. This affected 37,000 recipients of the device manufactured by DePuy in the United States, and 93,000 patients around the world.
Class Action lawyers for the DePuy Pinncle inform that you mist file your lawsuit now or run the risk of missing out.